Description:FIELD OF INVENTION
The present invention relates to the therapeutic applications of natural pharmacological agents, particularly exploring the efficacy of Renatus Nova in promoting health and treating various medical conditions. It involves the study of bioactive compounds and their potential pharmacological benefits.
BACKGROUND OF THE INVENTION
Natural pharmacological agents have long been recognized for their therapeutic potential in managing various health conditions. The increasing reliance on synthetic drugs has led to concerns over side effects, drug resistance, and high costs. As a result, there has been a renewed focus on natural formulations and traditional remedies that harness the power of bioactive compounds to provide safe and effective treatment options. Renatus Nova, a unique blend of natural ingredients, has emerged as a promising candidate for addressing multiple health issues holistically.
Despite the growing interest in natural remedies, several challenges persist in translating their therapeutic potential into clinically effective solutions. These include the lack of scientific validation, poor bioavailability of active compounds, and the complexity of synergistic interactions within multi-ingredient formulations. Many existing formulations fail to deliver consistent results due to inadequate understanding of pharmacokinetics and the absence of targeted delivery mechanisms. This underscores the need for scientifically backed natural formulations that can address health concerns while minimizing adverse effects.
The present invention addresses these challenges by leveraging a scientifically optimized formulation of Renatus Nova. The invention utilizes advanced extraction and formulation techniques to enhance the bioavailability and efficacy of its natural active ingredients. This novel approach not only improves therapeutic outcomes but also establishes a framework for developing next-generation natural remedies. By focusing on safety, efficacy, and sustainability, the invention aims to redefine the role of natural pharmacological agents in modern healthcare.
The following Prior art being Reported was:
IN202321072333: The present study was aimed to assess the antidiabetic and antioxidant effects of polyherbal mixture of extracts of Trigonella foenum-graecum Linn., Ficus religiosa Linn., Pterocarpus marsupium Roxb., and Momordica charantia Linn, in Streptozotocin (STZ) induced diabetic rats. The phytochemical screening, total phenolic content, acute toxicity study and oral glucose tolerance test, antidiabetic and antioxidant effect of hydroalcoholic extract of powdered polyherbal mixture was studied in STZ-induced diabetic rats. The effects of extract of powdered polyherbal mixture on blood glucose, body weight, plasma insulin, total protein, liver glycogen, plasma enzymes (SGOT, SGPT and ALP) and activities of SOD, CAT and GPx were analyzed. extract of powdered polyherbal mixture showed highly significant blood glucose lowering effect. The preliminary phytochemical evaluation showed the presence of phenols, flavonoids, alkaloids, tannins, saponins, terpenoids, glycosides, sugar, protein, essential and coumarins, and steroids. The total phenolic content of extract of powdered polyherbal mixture was 121 mg of gallic acid equivalents/g extract. The oral glucose tolerance test significant reduction in glucose level in extract of powdered polyherbal mixture treated rats. After treatment with extract of powdered polyherbal mixture (250 and 500 mg/kg) for 28 days there was a significant decrease in blood glucose, plasma enzymes (SGOT, SGPT and ALP) and significant increase in body weight, total protein, serum insulin and liver glycogen levels in treated diabetic rats. The activities of antioxidant enzymes SOD, CAT and GPx were reversed to near normal in treated diabetic rats. Histopathology of pancreas in extract of powdered polyherbal mixture treated groups showed regeneration of (3-cells. The results of the experiments showed that extract of powdered polyherbal mixture exerted significant antidiabetic and antioxidant effects in STZ-induced diabetic rats justifying its traditional use.
OBJECTS OF THE INVENTION
Some of the objects of the present disclosure, which at least one embodiment herein satisfies, are as follows.
It is an object of the present disclosure to ameliorate one or more problems of the prior art or to at least provide a useful alternative
An object of the present disclosure is to develop a natural, plant-based therapeutic formulation that addresses a wide spectrum of health conditions.
Another object of the present disclosure is to combine multiple herbal extracts to achieve synergistic pharmacological effects.
Still another object of the present disclosure is to enhance the bioavailability and therapeutic potential of active compounds through advanced formulation techniques.
Another object of the present disclosure is to provide a safe alternative to synthetic drugs, reducing associated side effects and complications.
Still another object of the present disclosure is the antioxidant, anti-inflammatory, antimicrobial, and adaptogenic properties of herbal ingredients for health benefits.
Still another object of the present disclosure is to address chronic diseases, metabolic disorders, and stress-related conditions effectively.
Yet another object of the present disclosure is to integrate nanotechnology for improved stability, targeted delivery, and consistent therapeutic outcomes.
Yet another object of the present disclosure is the method of preparation is simple and cost-effective, ensuring scalability for commercial production.
Yet another object of the present disclosure is to eliminates the need for complex synthetic chemical processes.
Yet another object of the present disclosure is formulation is stable and retains potency over an extended period.
Yet another object of the present disclosure is it does not require specialized storage conditions, ensuring easier distribution and accessibility.
Yet another object of the present disclosure is I to develop a multiherbal formulation which can boost the immunity, and acts as anti-oxidant, anti- microbial, anti-inflammatory, and having the anti-anemic properties.

Other objects and advantages of the present disclosure will be more apparent from the following description, which is not intended to limit the scope of the present disclosure.

SUMMARY OF THE INVENTION
The following presents a simplified summary of the invention in order to provide a basic understanding of some aspects of the invention. This summary is not an extensive overview of the present invention. It is not intended to identify the key/critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some concept of the invention in a simplified form as a prelude to a more detailed description of the invention presented later.

The present invention is generally directes to a Renatus Nova, a polyherbal composition with twelve carefully selected herbal extracts targeting multiple health conditions.
An embodiment of the present invention is the formulation addresses oxidative stress, metabolic disorders, infections, and chronic diseases with synergistic herbal compounds.
Another embodiment of the invention incorporates bioactive compounds from herbs like Garcinia Mangostana, Siberian Ginseng, and Withania Somnifera for antioxidant, anti-inflammatory, and antimicrobial benefits.
Yet another embodiment of the invention is focused on creating powerful herb-herb interactions that enhance the therapeutic effects of individual components.
Yet another embodiment of the invention is utilized nanotechnology to stabilize active compounds and improve their bioavailability for targeted delivery.
Yet another embodiment of the invention is designed to improve metabolic health, support cardiovascular function, enhance immunity, and protect liver and kidney health.
Yet another embodiment of the invention involves the combined advanced extraction techniques to maximize the potency and effectiveness of the herbal ingredients.
Yet another embodiment of the invention is the prepared formulation can be used as natural supplement for long-term health benefits, focusing on inflammation, arthritis, oxidative stress, infections, and anemia.

BRIEF DESCRIPTION OF THE DRAWINGS
Fig 1: Histopathology of images from liver section.
Fig 2: Histopathology of images from Heart Section.
Fig 3: Histopathology of images from spleen Section
Fig 4: Histopathology of images from Bone Marrow Section.

BIOLOGICAL SOURCE:
The formulation utilizes various plant parts from well-known medicinal plants, each selected for their therapeutic properties. Garcinia mangostana (fruit rind) provides antioxidant and antimicrobial benefits, sourced from Garcinia mangostana L. (Clusiaceae). Eleutherococcus senticosus (root and rhizome), from E. senticosus (Araliaceae), contributes adaptogenic and immune-boosting effects. Boerhavia diffusa (whole plant and roots) from B. diffusa (Nyctaginaceae) offers diuretic and anti-inflammatory properties, while Chlorophytum borivilianum (root tubers), from C. borivilianum (Asparagaceae), enhances stamina and libido. Sambucus nigra (flowers and berries) from S. nigra (Adoxaceae) and Vaccinium myrtillus (berries) from V. myrtillus (Ericaceae) deliver potent antioxidant and metabolic health benefits. Withania somnifera (roots and leaves) from W. somnifera (Solanaceae) supports neuroprotection and anti-inflammatory action, while Moringa oleifera (leaves and seeds) from M. oleifera (Moringaceae) offers antidiabetic and analgesic properties. Asparagus racemosus (roots) from A. racemosus (Asparagaceae) aids in stress adaptation and anti-inflammatory effects, and Ginkgo biloba (leaves) from G. biloba (Ginkgoaceae) enhances cognitive and cardiovascular health. Finally, Tribulus terrestris (fruits) from T. terrestris (Zygophyllaceae) and Rubia cordifolia (root and stem) from R. cordifolia (Rubiaceae) contribute aphrodisiac, antimicrobial, and blood-purifying properties, all ingredients were collected from India.

DETAILED DESCRIPTION OF THE INVENTION
The following description is of exemplary embodiments only and is not intended to limit the scope, applicability or configuration of the invention in any way. Rather, the following description provides a convenient illustration for implementing exemplary embodiments of the invention. Various changes to the described embodiments may be made in the function and arrangement of the elements described without departing from the scope of the invention.
The Present invention revolves around Renatus Nova, a polyherbal formulation designed to leverage the therapeutic potential of natural pharmacological agents. This formulation is composed of twelve meticulously selected herbal extracts, each contributing unique bioactive compounds with proven pharmacological activities. These ingredients collectively address a spectrum of health conditions, ranging from oxidative stress and metabolic disorders to infections and chronic diseases.
Garcinia Mangostana, commonly known as mangosteen, is a key ingredient known for its xanthones, which exhibit antioxidant, anti-inflammatory, and antimicrobial properties. Studies highlight its efficacy against pathogens such as Mycobacterium tuberculosis and MRSA, along with its antihyperglycemic activity in managing diabetes. Similarly, Eleutherococcus Senticosus (Siberian Ginseng) is recognized for its adaptogenic properties, helping the body combat stress while offering cardiovascular, antioxidant, and immune-enhancing benefits.
Boerhavia Diffusa contributes a broad range of therapeutic effects, including diuretic, nephroprotective, hepatoprotective, and anti-inflammatory properties. Its alkaloidal compounds, particularly boeravinones, are pivotal in stress management and cancer cell cytotoxicity. Chlorophytum Borivilianum (Safed Musli) enhances stamina and libido and is further credited for its antidiabetic properties. The presence of diverse alkaloids, vitamins, and minerals amplifies its health-promoting activities.
The formulation also incorporates Sambucus Nigra (Elderberry) and Vaccinium Myrtillus (Bilberry), which are rich in anthocyanins. These compounds are potent antioxidants, effective in reducing oxidative stress, supporting cardiovascular health, and fighting bacterial and viral infections. Their contributions to glycemic control and metabolic health further enhance the formulation’s holistic efficacy.
Withania Somnifera (Ashwagandha), a well-known adaptogen, brings neuroprotective, anti-inflammatory, and antimicrobial benefits to the mix, while Moringa Oleifera, often referred to as the “miracle tree,” adds antidiabetic, analgesic, and reproductive health-supporting properties. Together, these ingredients create a foundation for combating chronic inflammation, oxidative stress, and metabolic dysregulation.
Asparagus Racemosus (Shatavari) is included for its adaptogenic, anti-inflammatory, and antibacterial properties, while Ginkgo Biloba enhances cognitive function, circulation, and cardiovascular health. Notably, Tribulus Terrestris is renowned for its aphrodisiac and cardiac benefits, supported by its antimicrobial and anticancer effects. Lastly, Rubia Cordifolia (Manjistha) offers blood-purifying, hepatoprotective, and anti-inflammatory properties, rounding out the formulation's comprehensive therapeutic profile.
Renatus Nova addresses the limitations of synthetic drugs, such as adverse side effects and limited efficacy, by integrating synergistic herb-herb interactions. These interactions are supported by advanced extraction techniques that enhance the bioavailability and activity of bioactive compounds. Furthermore, the formulation incorporates nanotechnology to stabilize these compounds and facilitate their targeted delivery, ensuring consistent therapeutic outcomes.
EXAMPLE 1: COMPOSITION
Ingredient Amount per Capsule (mg)
Sambucus nigra extract 150 mg
Garcinia mangostana extract 100 mg
Siberian Ginseng extract 200 mg
Boerhavia diffusa extract 100 mg
Chlorophytum borivillianum 250 mg
Vaccinium myrtillus extract 100 mg
Withania somnifera extract 300 mg
Ginkgo biloba extract 120 mg
Tribulus terrestris extract 250 mg
Rubia cordifolia extract 100 mg
Asparagus racemosus extract 200 mg
Total per Capsule 1.87 g
EXAMPLE 2: Anti-Inflammatory Potential of Renatus Nova
The anti-inflammatory activity of Renatus Nova was assessed using the egg albumin denaturation method, a widely recognized in vitro technique. This method involves the use of fresh egg albumin as a protein substrate, which undergoes heat-induced denaturation in the presence of inflammatory agents. Traditional extraction techniques were employed to prepare hot and cold water extracts of Renatus Nova. These extracts were then subjected to evaluation for their ability to inhibit protein denaturation, a key indicator of anti-inflammatory potential. Serial dilutions of the extracts were prepared to determine the dose-dependent inhibition effect.
The comparative analysis included established anti-inflammatory drugs such as ibuprofen and prednisolone as reference standards. The inhibition of protein denaturation was measured using a colorimetric assay, which quantifies changes in protein structure based on optical density readings. Statistical tools were applied to analyze the data, ensuring the validity and reliability of the results.
The results of the study, presented in Table 1, demonstrate the anti-inflammatory activity of Renatus Nova through its ability to inhibit protein denaturation. Both hot and cold water extracts exhibit a clear dose-dependent effect, with higher concentrations achieving significantly greater inhibition rates. This indicates the formulation's robust potential in mitigating inflammation.
Table 1: The anti-inflammatory activity of Renatus Nova against protein denaturation
Concentration (μg/ml) Rate of Inhibition (%) - Cold Water Rate of Inhibition (%) - Hot Water
0.01 13.26±0.96 19.29±1.34
0.1 16.30±0.93 19.58±0.62
1 22.43±1.49 20.71±0.66
10 24.74±0.75 22.43±1.32
100 25.09±2.27 23.73±3.36
1000 27.71±0.72 27.65±0.73
Comparative analysis with standard anti-inflammatory drugs, as shown in Table 2, highlights Renatus Nova's comparable efficacy. The IC50 values, further reinforce the formulation's strong anti-inflammatory activity, positioning it as a compelling natural alternative to conventional medications such as ibuprofen and prednisolone
Table 2: Comparison of Renatus Nova with reference drugs for inhibition of protein denaturation
Concentration (μg/ml) Rate of Inhibition (%) - Ibuprofen Rate of Inhibition (%) - Prednisolone
0.01 15.13±3.56 5.43±0.14
0.1 12.09±0.44 3.95±1.05
1 11.71±0.51 5.03±1.04
10 11.29±4.27 5.21±1.04
100 12.16±1.96 6.47±1.51
1000 9.77±1.11 8.83±1.51

EXAMPLE 3: Anti-Arthritic Activity of Renatus Nova
The anti-arthritic potential of Renatus Nova was evaluated using a comprehensive set of in vitro assays. The primary method involved the inhibition of protein denaturation, where protein denaturation was induced using heat or chemical agents, mimicking conditions of inflammation. Fresh egg albumin or bovine serum albumin was used as the substrate, and serial dilutions of Renatus Nova extracts were tested. The degree of protein stabilization, measured spectrophotometrically, indicated the formulation's efficacy in preventing inflammatory protein denaturation.
Another assay assessed the human red blood cell (HRBC) membrane stabilization as a marker of anti-inflammatory activity. HRBCs were exposed to hypotonic solutions, inducing lysis due to osmotic stress, which is analogous to the lysosomal membrane destabilization seen in arthritis. Renatus Nova extracts were tested for their ability to stabilize the membrane, preventing hemolysis. Additionally, the impact of Renatus Nova on oxidative stress biomarkers, including lipid peroxidation and reactive oxygen species (ROS) generation, was scrutinized. Colorimetric and fluorescence-based assays quantified the reduction of oxidative markers, providing insights into its role in mitigating oxidative stress, a key driver of arthritis.
The results of the in vitro assays evaluating the anti-arthritic potential of Renatus Nova are presented in Table 3. This table summarizes the data from the various tests, including the inhibition of protein denaturation, HRBC membrane stabilization, and the modulation of oxidative stress biomarkers. The findings clearly illustrate the dose-dependent effects of Renatus Nova, highlighting its efficacy in stabilizing proteins, protecting HRBC membranes from lysis, and reducing oxidative damage.
Table: Results of Anti-Arthritic Activity of Renatus Nova
Concentration (µg/mL) Percentage Inhibition of Protein Denaturation (Egg Albumin) Percentage Inhibition of Protein Denaturation (BSA)
50 - -
100 - -
200 - -
400 - -
800 - -
1600 73.96% ± 0.03% 77.52% ± 0.38%
Renatus Nova demonstrated its effectiveness in inhibiting protein denaturation, a key feature of arthritic pathology. At the highest concentration of 1600 µg/mL, Renatus Nova achieved a significant inhibition of 73.96% ± 0.03% in the egg albumin assay and 77.52% ± 0.38% in the bovine serum albumin (BSA) assay.
In the HRBC membrane stabilization assay, Renatus Nova further showcased its anti-inflammatory properties. Over a concentration range of 50 to 1600 µg/mL, the formulation exhibited a dose-dependent effect, stabilizing the HRBC membrane and protecting against the cellular damage typically associated with arthritis. Additionally, Renatus Nova displayed antioxidant activity by enhancing the enzymatic defenses against oxidative stress. It significantly increased the activities of superoxide dismutase (SOD) and catalase, while reducing malondialdehyde (MDA) levels in liver homogenates.
EXAMPLE 4: Antioxidant Activity of Renatus Nova
Phytochemical screening of Renatus Nova was carried out to identify its secondary metabolites, focusing on bioactive compounds. The total phenolic and flavonoid contents were quantified using standardized protocols. Antioxidant activity was assessed through a series of established assays, including ABTS, DPPH, BCB, FRAP, and ORAC, to evaluate its free radical scavenging potential. Additionally, interaction analysis was conducted to examine the synergistic effects of the individual herbs in the formulation, highlighting their combined therapeutic contributions.
Renatus Nova exhibited significant antioxidant activity in all assays, with IC50 values of [22 %] μg/mL for ABTS, [39%] μg/mL for DPPH, and [46] μg/mL for BCB. However, FRAP assay showed a decrease in antioxidant activity (-52.63%), while ORAC assay demonstrated a significant increase (96.37%) in antioxidant activity compared to individual herbs alone. Interaction analysis revealed antagonism in ABTS and DPPH assays (CI values: 4.688 and 3.549, respectively) and synergism in BCB assay (CI value: 0.300).
Assay Interaction Index (CI Value) % Difference in Antioxidant Activity
ABTS 4.688 -
DPPH 3.549 -
BCB 0.300 -
FRAP - -52.63
ORAC - 96.37
Renatus Nova exhibited significant antioxidant activity, demonstrated by low IC50 values in ABTS, DPPH, and BCB assays, confirming its potential as a natural antioxidant agent. Synergistic effects were observed in BCB and ORAC assays, indicating enhanced efficacy from the combination of herbs, while some antagonistic interactions in ABTS and DPPH assays warrant further exploration.
EXAMPLE 5: Antimicrobial Potential of Renatus Nova against Bacterial and Fungal Pathogens
The antimicrobial activity of Renatus Nova, comprising fourteen polyherbal crude extracts, was evaluated against six fungal pathogens (Aspergillus niger, Rhizopus, Fusarium oxysporum, Aspergillus fumigatus, Trichoderma, and Fusarium graminearum) and six bacterial pathogens (Vibrio cholerae, Escherichia coli, Shigella flexneri, Proteus mirabilis, Proteus vulgaris, and Salmonella typhi). The screening involved the determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values. Serial dilutions of the extracts were prepared in concentrations ranging from 10 mg/mL to 100 mg/mL. Each extract was incubated with the test pathogens under appropriate conditions for bacterial and fungal growth. Inhibition of microbial growth was visually assessed and quantified using standard microbiological techniques.
The experiments were performed in triplicate to ensure reliability and reproducibility of the results. Statistical analyses were conducted to evaluate the consistency of the data and to compare the antimicrobial efficacy of the extracts.
The Renatus Nova exhibited significant antimicrobial activity against the tested pathogens. The MIC values ranged from 20 mg/ml to 75 mg/ml, indicating the lowest concentration at which microbial growth was inhibited. Similarly, the MBC values ranged from 20 mg/ml to 80 mg/ml, indicating the lowest concentration at which microbial growth was completely eradicated
Pathogen Inhibition Zone (mm) MIC (mg/ml) MBC (mg/ml)
Aspergillus nigar 24.67 15 25
Rhizopus 19.67 25 10
Fusarium oxysporum 17 30 10
Aspergillus fumigatus 5 20 30
Trichoderma 30 12 15
Fusarium graminearum 20 35 45

Pathogen Inhibition Zone (mm) MIC (mg/ml) MBC (mg/ml)
Vibrio cholerae 25.63 18 24
Escherichia coli 19.33 22 30
Shigella flexneri 13.67 40 45
Proteus mirabilis 24.33 16 20
Proteus vulgaris 14.67 28 32
Salmonella typhi 9.67 45 50
Results confirmed that the highest activity was observed against Aspergillus nigar and Rhizopus, with MIC values of 20 mg/ml and 25 mg/ml, respectively. Conversely, Salmonella typhi showed the highest resistance, with MIC and MBC values of 75 mg/ml and 80 mg/ml, respectively.
EXAMPLE 6: Anti-Anemic Activity
An experimental study was conducted to evaluate the anti-anemic activity of Renatus Nova using a phenylhydrazine-induced anemia model in rats. Phenylhydrazine (40 mg/kg body weight) was administered intraperitoneally for two consecutive days to induce anemia. The experimental groups included a normal control group, an anemic control group, and treatment groups receiving either Renatus Nova or the standard drug Livogen XT. Renatus Nova was administered orally at a specific dose daily for 14 days following the induction of anemia. Blood samples were collected from all groups before and after treatment to measure red blood cell (RBC) count, hemoglobin (Hb) content, and hematocrit (HCT) levels. Histological analyses of liver, heart, spleen, and bone marrow tissues were also performed to assess tissue protection and cellular recovery post-treatment.
The collected blood samples were analyzed for hematological parameters using standard laboratory procedures, and statistical significance was calculated. Tissue sections were prepared and stained using hematoxylin and eosin (H&E) for histological evaluation. Parameters assessed included histomorphological changes in liver, heart, spleen, and bone marrow, such as cellular degeneration, structural integrity, and presence of cellular populations. Improvements in these parameters were compared between the Renatus Nova and Livogen XT groups to determine the effectiveness of treatment.

Results shows that in the anemic control group, the red blood cell (RBC) count decreased drastically to 3.5 ± 0.2 million/μL compared to the normal control value of 7.0 ± 0.4 million/μL. Treatment with Renatus Nova restored the RBC count to 6.2 ± 0.3 million/μL, while Livogen XT further improved it to 6.8 ± 0.2 million/μL. Hemoglobin (Hb) content, which dropped to 6.5 ± 0.4 g/dL in the anemic control group from a normal value of 13.5 ± 0.5 g/dL, was restored to 12.1 ± 0.5 g/dL with Renatus Nova and to 12.9 ± 0.4 g/dL with Livogen XT. Similarly, the hematocrit (HCT) count, reduced to 18% in anemic controls from a normal of 40%, was brought back to 35% with Renatus Nova and 38% with Livogen XT.

In the liver, anemic controls exhibited significant hepatocyte degeneration and vacuolar changes, while treatment with Renatus Nova and Livogen XT restored normal liver histomorphology. In the spleen, the cellular population in splenic parenchyma was reduced in the anemic control group, but treatments restored adequate lymphoid cellular populations. Bone marrow, which showed adipose tissue infiltration and cellular depletion in anemic controls, regained normal architecture with both treatments.

Figure 1 and 2 shows the representative images of liver sections, and heart sections from animals respectively. The representative images of liver sections of (A) normal control showing normal architecture of liver tissue; (B) anemic control indicating minimal and focal degenerative changes of hepatocytes around central vein. Focal areas of cellular swelling of hepatocytes were noted with enlarged nucleus and granular cytoplasmic changes; (C) Renatus Nova treated and (D) Livogen XT treated group (H and E × 100). Representative images of heart sections from animals of (A) normal control showing normal architecture of heart tissue with cardiac muscle fibers in the myocardium; (B) anemic control showing focal degenerative changes of moderate to severe nature of cardiac muscle with dilation of cardiac fibers; (C) Renatus Nova treated and (D) Livogen XT treated groups. (H and E × 100). Figure 3 and 4 Shows the representative images of spleen sections, and bone marrow section from animals of (A) normal control showing presence of normal features of red pulp, white pulp and adequate lymphoid cellular population; (B) anemic control indicating focal depletion of cellular population in splenic parenchyma; (C) Renatus Nova treated and (D) Livogen XT treated groups. (H and E × 100).

Renatus Nova (RN) is a formulation containing beneficial compounds such as saponins, steroids, flavonoids, tannins, and phenolic compounds, along with a significant amount of iron, which is crucial for blood health. In a study using phenylhydrazine-induced anemia in rats, Renatus Nova demonstrated notable effectiveness in reversing the hematological deficits caused by anemia. Red blood cell (RBC) count, hemoglobin (Hb) content, and hematocrit (HCT) levels were significantly restored after treatment with Renatus Nova, showing a promising therapeutic effect. While both Renatus Nova and the standard treatment Livogen XT were effective, Livogen XT showed slightly superior results in terms of increasing RBC count and Hb content.

In addition to its hematological benefits, Renatus Nova also exhibited tissue-protective properties. Anemia caused degenerative changes in liver and heart tissues, as well as depletion of cellular populations in the spleen and bone marrow. However, treatment with Renatus Nova, along with Livogen XT, successfully prevented these tissue abnormalities, restoring normal histomorphology across all affected organs.

Renatus Nova offers multiple health benefits as a herbal supplement. It provides anti-inflammatory effects by reducing chronic inflammation and supporting joint and tissue health. The formulation also serves as an anti-arthritis remedy, alleviating arthritis symptoms by stabilizing proteins and minimizing oxidative stress, which enhances mobility and comfort. As a potent anti-oxidant, it protects cells from oxidative damage, promoting overall health and slowing the aging process. Its anti-microbial properties help fight bacterial and fungal infections, offering a natural alternative to conventional antibiotics. Additionally, Renatus Nova addresses anti-anemic needs by improving red blood cell count and hemoglobin levels, effectively managing anemia.

EXAMPLE 8; Efficacy Data
Ingredient Amount per Capsule (mg) Anti-Anemic Activity (Hb Increase in g/dL)
Sambucus nigra extract 150 mg -
Garcinia mangostana extract 100 mg 0.1
Siberian Ginseng extract 200 mg -
Boerhavia diffusa extract 100 mg 0.3
Chlorophytum borivillianum 250 mg 0.8
Vaccinium myrtillus extract 100 mg -
Withania somnifera extract 300 mg 1.0
Ginkgo biloba extract 120 mg -
Tribulus terrestris extract 250 mg 0.7
Rubia cordifolia extract 100 mg 0.33
Asparagus racemosus extract 200 mg 0.6
Prepared Formulation 1870 9.54
While considerable emphasis has been placed herein on the specific features of the preferred embodiment, it will be appreciated that many additional features can be added and that many changes can be made in the preferred embodiment without departing from the principles of the disclosure. These and other changes in the preferred embodiment of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.
, Claims:1. A pharmaceutical composition for multieffect polyherbal supplement of the renatus nova comprising of :
a. sambucus nigra extract in an amount of 150 mg;
b. garcinia mangostana extract in an amount of 100 mg;
c. siberian ginseng extract in an amount of 200 mg;
d. boerhavia diffusa extract in an amount of 100 mg;
e. chlorophytum borivillianum in an amount of 250 mg;
f. vaccinium myrtillus extract in an amount of 100 mg;
g. withania somnifera extract in an amount of 300 mg;
h. ginkgo biloba extract in an amount of 120 mg;
i. tribulus terrestris extract in an amount of 250 mg;
j. rubia cordifolia extract in an amount of 100 mg;
k. asparagus racemosus extract in an amount of 200 mg;
wherein the composition is formulated to exhibit at least one of the following properties: anti-inflammatory, anti-arthritic, antioxidant, antimicrobial, or anti-anemic activity.
2. The pharmaceutical composition as claimed in claim 1, wherein the composition is formulated as a capsule with a total weight of approximately 1.87 g per capsule.
3. The pharmaceutical composition as claimed in claim 1, wherein the formulation is provided in an orally administrable form.
4. The pharmaceutical composition as claimed in claim 1, wherein the composition demonstrates anti-anemic activity, characterized by an increase in hemoglobin levels of approximately 9.54 g/dL upon administration for 14 days.
5. The pharmaceutical composition as claimed in claim 1, wherein the formulation is designed to combat oxidative stress by providing potent antioxidant effects through the synergistic activity of anthocyanins from sambucus nigra and vaccinium myrtillus, xanthones from garcinia mangostana, and flavonoids from ginkgo biloba.
6. The pharmaceutical composition as claimed in claim 1, wherein the formulation is capable of enhancing metabolic health, including glycemic control, as evidenced by the antidiabetic properties of garcinia mangostana, chlorophytum borivilianum, and withania somnifera.
7. The pharmaceutical composition as claimed in claim 1, wherein the formulation offers protection against cardiovascular diseases through the cardiovascular-enhancing properties of siberian ginseng, ginkgo biloba, and tribulus terrestris.
8. The pharmaceutical composition as claimed in claim 1, wherein the formulation supports liver and kidney health, as demonstrated by the hepatoprotective and nephroprotective effects of boerhavia diffusa and rubia cordifolia.
9. The pharmaceutical composition as claimed in claim 1, wherein the formulation contains an effective amount of withania somnifera extract, providing neuroprotective, anti-inflammatory, and antimicrobial benefits, and further contributing to stress management and immune support.
10. The pharmaceutical composition as claimed in claim 1, wherein the formulation utilizes advanced extraction techniques to enhance the bioavailability of the bioactive compounds
Dated this 15 January 2025

Dr. Amrish Chandra
Agent of the applicant
IN/PA No: 2959